Anavex Life Sciences Corp (AVXL)

[powerwalker]

While we read constantly from certain posters that 99% of all Alzheimer's drugs failed a P3 after being successful in the respective P2 and, therefore, they imply 2-73 will fail, too, will those posters please tell me what was the nature of the P2 success ... Safety? Efficacy? Dosage?

I don't know the answer and want to understand the correlation between those failed drugs' P2/P3 and 2-73's and the eventual P3 for 2-73. If those drugs did report efficacy, was it a large % of participants? If that were true, how did the BP companies explain the failure in the P3 if efficacy were shown in P2? How did that benefit go up in smoke in the P3?

TIA